AUTHORS
Gang An, MD, Baijun Fang, PhD2, Xun Lai, MD3, Hui-Han Wang4, Lijie Xing, MD5, Shi Minxia, MD, PhD6, Zhimin Zhai Jr, phD7, Liping Su, MD8, chao Li, N/A9, Jie Ma10, Dexiao Kong11, Deqing Kong12, Fuling Zhou13, Haiping Yang, MD14, Qiangqiang Zhao15, Li Yang16, Jingdong Zhang17, Jinqiao Zhang18, Lina Zhao, PhD19, Ying Lu20, Yinghui Lai21, Hao Zhang22, Xiangmin Tong23, Ying Wang, MD24, Na Gao25, Xuzhang Lu, PhD26, Yanping Ma, MD27, Qike Zhang, MD28, Jianhua Qu, MD29, Xiaobo Du30, Lihua Wang31, Peng Shao32, Xin'ai Yang33, Qiong Wu34
AFFILIATIONS
1 Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2 Henan Cancer Hospital, Zhengzhou, China
3 Yunnan Cancer Hospital, Kunming, China
4 Shengjing Hospital of China Medical University, Shenyang, China
5 Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, China
6 The First Affiliated Hospital of Kunming Medical University, Kunming, China
7 The Second Affiliated Hospital of Anhui Medical University, Hefei, China
8 Shanxi Cancer Hospital (Shanxi Cancer Institute), Taiyuan, China
9 Nanyang Central Hospital, Nanyang, China
10 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
11 The Second Qilu Hospital of Shandong University, Jinan, China
12 The Second Qilu Hospital of Shandong University, Jinan, China
13 Zhongnan Hospital of Wuhan University, Wuhan, China
14 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
15 Liuzhou People's Hospital, Liuzhou, China
16 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
17 Ganzhou People's Hospital, Ganzhou, China
18 Hebei Medical University Third Hospital, Shijiazhuang, China
19 Harbin Medical University Cancer Hospital, Harbin, China
20 The Affiliated People's Hospital of Ningbo University, Ningbo, China
21 The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
22 Affiliated Hospital of Jining Medical University, Jining, China
23 Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China
24 Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China
25 Shandong Medical and Pharmaceutical University Hospital, Jinan, China
26 Changzhou Second People's Hospital, Changzhou, China
27 Second Hospital of Shanxi Medical University, Taiyuan, China
28 Gansu People's Hospital, Lanzhou, China
29 The First Teaching Hospital of Xinjiang Medical University, Urumqi, China
30 Mianyang Central Hospital, Mianyang, China
31 Qilu Pharmaceutical Co., Ltd., Jinan, China
32 Qilu Pharmaceutical Co., Ltd., Jinan, China
33 Qilu Pharmaceutical Co., Ltd., Jinan, China
34 Qilu Pharmaceutical Co., Ltd., Jinan, China
ABSTRACT
Background: QLS32015, a GPRC5D×CD3 bispecific antibody, showed manageable safety profile and encouraging preliminary efficacy in pts with RRMM in phase 1a/1b study (ASH 2025, Blood 2025;146 (Suppl 1):4049). Anti-GPRC5D bispecific antibody based combination therapies, including immunomodulatory imide drug (IMiD), anti-CD38 monoclonal antibody (mAb), and proteasome inhibitor (PI), may achieve synergistic activity against RRMM.
Methods: In this ongoing multicenter, open-label phase 2 trial, eligible multiple myeloma pts diagnosed by 2016 IMWG criteria who had received ≥1 prior line of therapy (LOT) and experienced disease relapse, progression, or intolerance to prior therapy. Pts were assigned to 4 cohorts and received QLS32015-based combination therapies. Each treatment cycle was 4-week. Cohort 1: QLS32015 plus pomalidomide. Cohort 2: QLS32015 plus QL2109 (a biosimilar of daratumumab). Cohort 3: QLS32015 plus QL2109 and pomalidomide. Cohort 4: QLS32015 plus bortezomib and lenalidomide. QLS32015 was administered via subcutaneous (SC) infusion every 2 weeks (Q2W) or every 4 weeks (Q4W), at 54 µg/kg or at 4 mg. QL2109 was administered via SC infusion at 1800 mg with follow intervals: weekly for Cycle 1–2, Q2W for Cycle 3–6, and Q4W from Cycle 7. Pomalidomide, bortezomib, and lenalidomide were administered per standard regimens. The primary endpoints were IMWG overall response rate (ORR) and minimal residual disease (MRD) negativity.
Results: As of May 20, 2026, 75 pts received QLS32015-based combination therapy (Cohort 1, N=6; Cohort 2, N=29; Cohort 3, N=34; Cohort 4, N=6). Median age was 61.0 years (of 35% pts ≥65 years old). Among them, 18.7% had extramedullary disease, 37.3% had high-risk cytogenetics, and 72.0% were R-ISS stage II/III. Median LOT was 2.5; 100% had prior IMiD; 57.3% had prior anti-CD38 mAb; 100% had prior PI; 33.3% had prior autologous stem cell transplant; and 5.3% had prior anti-B cell maturation antigen CAR-T therapy. In 5 efficacy-evaluable pts in Cohort 1, the ORR was 80.0%, with 60.0% ≥very good partial response (VGPR), 40.0% ≥complete response (CR); the median time to response (mTTR) was 1.31 months. In 18 efficacy-evaluable pts in Cohort 2, the ORR was 94.4%, with 72.2% ≥VGPR, 22.2% ≥CR, and 50% CR-MRD-negative; the mTTR was 1.28 months. In 28 efficacy-evaluable pts in Cohort 3, the ORR was 89.3%, with 71.4% ≥VGPR, 17.9% ≥CR, and 40% CR-MRD-negative; the mTTR was 1.35 months. In 6 efficacy-evaluable pts in Cohort 4, the ORR was 66.7%, with 50.0% ≥VGPR, 33.3% ≥CR, and 50% CR-MRD-negative; the mTTR was 1.43 months. In difficult-to-treat subgroups in Cohort 2, pts with prior anti-CD38 mAb exposure: ORR 88.9%, 66.7% ≥VGPR; pts aged ≥65 years: ORR 100%, 62.5% ≥VGPR. In Cohort 3, pts with prior anti-CD38 mAb exposure: ORR 88.9%,72.2% ≥VGPR; pts aged ≥65 years: ORR 88.9%,55.6% ≥VGPR. Treatment-related adverse events (TRAEs) of any grade (Gr) occurred in 74 (98.7%) pts across 4 cohorts, 6 (100%) pts in Cohort 1, 28 (96.6%) pts in Cohort 2, 34 (100%) in Cohort 3, 6 (100%) in Cohort 4. One patient discontinued treatment due to TRAEs in Cohort 2, treatment-related death occurred in one patient in Cohort 2 and 3, respectively. The most common TRAE was platelet count decreased (82.7%). The most common infection was pneumonia (28.0%; Gr ≥3, 21.3%) across 4 cohorts, 27.6% (Gr ≥3, 20.7%) in Cohort 2, 38.2% (Gr ≥3, 29.4%) in Cohort 3. Rash, skin and nail GPRC5D-related TRAEs occurred in 58.7% (Gr ≥3, 6.7%), 50.7% (Gr ≥3, 2.7%), and 18.7% (Gr ≥3, 0) of pts, respectively. Oral mucositis, dysgeusia and weight loss occurred in 36%, 34.7%, and 17.3% of pts, which were all Gr 1 or 2. Cytokine release syndrome (CRS) occurred in 37 (49.3%) pts (Gr ≥3, 1.3%) across 4 cohorts, 13 (44.8%) pts in cohort 2, 17 (50.0%) pts in cohort 3, no Gr ≥3 CRS occurred in cohort 2 and 3. Mainly CRS occurred in the first cycle, with a median onset time of 40.3 h (range, 11.8–270.7) and median duration of 3.0 days. No immune effector cell-associated neurotoxicity syndrome (ICANS) occurred.
Conclusions: QLS32015-based combination therapies in pts with RRMM showed promising preliminary efficacy in QLS32015 plus QL2109, and QLS32015 plus QL2109 and pomalidomide, especially in difficult-to-treat subgroups with prior anti-CD38 mAb exposure and pts aged ≥65 years. QLS32015-based combination therapies were well-tolerated with manageable safety profile among pts with RRMM, which was generally consistent with QLS32015 monotherapy; no ICANS occurred.
DISCLOSURES
Gang An, MD: No relevant conflicts of interest to declare.